Search details
1.
"Empathy without sympathy": An analysis of support-related preferences among young adult cancer survivors.
J Psychosoc Oncol
; 40(4): 457-472, 2022.
Article
in English
| MEDLINE | ID: mdl-33905313
2.
Cancer-Related Decision-Making Among Adolescents, Young Adults, Caregivers, and Oncology Providers.
Qual Health Res
; 31(13): 2355-2363, 2021 11.
Article
in English
| MEDLINE | ID: mdl-34382889
3.
The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.
Blood
; 127(18): 2219-30, 2016 05 05.
Article
in English
| MEDLINE | ID: mdl-26851293
4.
Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies.
Invest New Drugs
; 33(3): 652-63, 2015 Jun.
Article
in English
| MEDLINE | ID: mdl-25777468
5.
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer.
Nature
; 458(7239): 732-6, 2009 Apr 09.
Article
in English
| MEDLINE | ID: mdl-19360080
6.
Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells.
Blood
; 120(19): 3958-67, 2012 Nov 08.
Article
in English
| MEDLINE | ID: mdl-22983447
7.
T Cell-intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia.
Mol Cancer Ther
; 22(9): 1040-1051, 2023 09 05.
Article
in English
| MEDLINE | ID: mdl-37420267
8.
MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma.
Blood
; 116(9): 1515-23, 2010 Sep 02.
Article
in English
| MEDLINE | ID: mdl-20525923
9.
Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.
Clin Cancer Res
; 22(1): 34-43, 2016 Jan 01.
Article
in English
| MEDLINE | ID: mdl-26561559
10.
Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors.
Clin Cancer Res
; 22(4): 847-57, 2016 Feb 15.
Article
in English
| MEDLINE | ID: mdl-26423795
11.
KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism.
PLoS One
; 10(12): e0144825, 2015.
Article
in English
| MEDLINE | ID: mdl-26709701
12.
Regulation of T cell receptor complex-mediated signaling by ubiquitin and ubiquitin-like modifications.
Am J Clin Exp Immunol
; 3(3): 107-23, 2014.
Article
in English
| MEDLINE | ID: mdl-25628960
13.
Preclinical activity of the oral proteasome inhibitor MLN9708 in Myeloma bone disease.
Clin Cancer Res
; 20(6): 1542-54, 2014 Mar 15.
Article
in English
| MEDLINE | ID: mdl-24486586
14.
The discovery of a reciprocal relationship between tyrosine-kinase signaling and cullin neddylation.
PLoS One
; 8(10): e75200, 2013.
Article
in English
| MEDLINE | ID: mdl-24124476
15.
Overcoming platinum resistance in preclinical models of ovarian cancer using the neddylation inhibitor MLN4924.
Mol Cancer Ther
; 12(10): 1958-67, 2013 Oct.
Article
in English
| MEDLINE | ID: mdl-23939375
16.
Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies.
Clin Cancer Res
; 17(23): 7313-23, 2011 Dec 01.
Article
in English
| MEDLINE | ID: mdl-21903769
17.
Insulin-like growth factor-binding protein 3 expression increases during immortalization of cervical keratinocytes by human papillomavirus type 16 E6 and E7 proteins.
Am J Pathol
; 161(2): 603-10, 2002 Aug.
Article
in English
| MEDLINE | ID: mdl-12163384
Results
1 -
17
de 17
1
Next >
>>